Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STORM: Sequencing SG vs T-DXd in HER2-Low/TROP2-High Metastatic Breast Cancer
NCT07368543Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Jan 2026
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
A Phase 2 trial of sacituzumab govitecan, trastuzumab deruxtecan in breast cancer, sponsored by Fudan University. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
sacituzumab govitecantrastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07368543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07368543.